VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2022 | State-of-the-art first-line therapy for mCRC

Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, explores the first-line treatment of patients with metastatic colorectal cancer (mCRC), including molecular drivers of disease such as microsatellite instability, as well as EGFR/BRAF/RAS mutations which can be targeted by immunotherapies or targeted therapies respectively. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter